Focus on Pitavastatin

Authors

  • Angelo Michele Carella Internal Medicine Department, "T. Masselli-Mascia" Hospital
  • Teresa Marinelli Internal Medicine Department, "T. Masselli-Mascia" Hospital
  • Armando Melfitano Internal Medicine Department, "T. Masselli-Mascia" Hospital
  • Michele Di Pumpo Internal Medicine Department, "T. Masselli-Mascia" Hospital
  • Matteo Conte Internal Medicine Department, "T. Masselli-Mascia" Hospital
  • Giovanni Modola San Pio" Pharmacy
  • Maria Chiara Puntonio Internal Medicine Department, "T. Masselli-Mascia" Hospital
  • Angelo Benvenuto

Keywords:

Pitavastatin, HMG-CoA reductase inhibitors, Statin therapy, Hyperlipidemia, Cardiovascular risk

Abstract

Currently, different statins are available for the treatment of dyslipidemia: Atorvastatin, Simvastatin, Rosuvastatin, Lovastatin, Pravastatin, and Fluvastatin; the newest entry in this class of drugs is Pitavastatin.

The purpose of the present study was to examine the latest evidences on Pitavastatin, more than 10 years after its first marketing and focuses on the most recent evidence regarding its differences with other available statins. A literature review of the last 3 years (January 2013 - January 2016) has been carried out via Pub Med. 193 obtained items were analysed.

Pitavastatin has been studied against other drugs in its class and has demonstrated high potency in reducing LDL-Cholesterol levels and increasing HDL-Cholesterol. Pitavastatin has demonstrated a significant reduction in atherosclerotic plaque volumes and several pleiotropic effects, which suggest its potential benefits in reducing cardiovascular risk.

At present, Pitavastatin don’t seem to have adverse effects on glucose metabolism; it has no adverse effects on renal function and currently there is no clinical evidence of Pitavastatin-induced hepatotoxicity. Pitavastatin has favorable pharmacokinetic and safety profiles and its characteristic structure provides significant efficacy at low doses.

Downloads

Published

2016-03-11

Issue

Vol. 3 No. 1 (2016)

Section

Articles

License

Policy for Journals/Articles with Open Access

Authors who publish with this journal agree to the following terms:
    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

  1. Authors are permitted and encouraged to post links to their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work

Policy for Journals / Manuscript with Paid Access

Authors who publish with this journal agree to the following terms:
    1. Publisher retain copyright .

  1. Authors are permitted and encouraged to post links to their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work .

Most read articles by the same author(s)